自拍无码精品一区二区|亚洲А∨天堂久久精品|国产日韩欧美一区二区视|亚洲av高清dvd丝袜|中文一级无码黄片精品视频|亚洲无码网站在线免费观看|免费无码又爽又刺激又污又黄|成人免费无码婬片在线观看免费

CSD00107

Ipilimumab

>95%

1mg/ml

PBS buffer PH7.5

CHO cells

Please contact with the lab for this information.

Ipilimumab (anti-CTLA-4) is an immunomodulatory monoclonal antibody directed against the cell surface antigen CTLA-4 and also a type of immune checkpoint inhibitor.Cytotoxic T-lymphocyte antigen-4 (CTLA-4) is an inhibitory molecule that competes with the stimulatory CD28 for binding to B7 on antigen presenting cells.3 CTLA-4 and CD28 are both presented on the surface of T-cells.3 Ipilimumab is a human IgG1 that binds CTLA-4, preventing the inhibition of T-cell mediated immune responses to tumors.

BMS-734016,MDX-010,MDX-CTLA-4

CTLA4/CD152[Homo sapiens]

Ipilimumab (anti-CTLA-4), is a fully humanized IgG1k monoclonal antibody produced by recombinant DNA technology in a CHO mammalian cell expression system, binding with high affinity to the extracellular domain of human (and Cynomolgus monkey) CTLA-4, and acting as an inhibitor of its complex functions. This essentially results in T-cell activation and proliferation, and in lymphocyte infiltration leading to tumor cell death. However, the enhancement of T effector cell function, combined with the inhibition of CD4+ Treg and CD8+ suppressive cell types, are considered essential for mediating the full therapeutic effects of ipilimumab. Ipilimumab can improve ATC proliferation, enhance the BiAb-mediated tumor-specific cytotoxicity, and increase cytokine synthesis, while it attenuates Treg activity as shown by decreased level of IL-10 secretion and reduced Treg population. Ipilimumab and nivolumab treatments could collaboratively enhance effector and memory T cell responses without inappropriately activating naive T cells.

Homo sapiens

IgG1-kappa

148000.00 Da

477202-00-9

Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
Store at +4°C short term (1-2 weeks).
Store at -20 °C 12 months.
Store at -80°C long term.

For research use only .